Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05689164 · ClinicalTrials.gov registry record · Phase 3
A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT05689164 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 7 participants.
The verdict
NCT05689164, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the safety and effects of an experimental gene therapy called fordadistrogene movaparvovec. We are seeking participants from previous Pfizer interventional studies. We will follow participants' experience in this study for 10 years after the end of their previous study. Participants will have 1 annual onsite visit and a few annual remote visits. The exact number of remote visits will be decided by their study doctor.
Interventions
- BIOLOGICAL fordadistrogene movaparvovec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2025-09-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05689164
The ClinicalTrials.gov registry entry for NCT05689164 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fordadistrogene movaparvovec is the first listed.
NCT05689164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05689164 about?
NCT05689164 is a clinical study titled "A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.". The purpose of this study is to understand the safety and effects of an experimental gene therapy called fordadistrogene movaparvovec. We are seeking participants from previous Pfizer interventional studies. We will follow participants' experience in this study for 10 years after the end of their pr...
What is the current status of trial NCT05689164?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2023-03-13. Estimated completion is 2025-09-24.
What interventions are being tested in trial NCT05689164?
The interventions under investigation include: fordadistrogene movaparvovec (BIOLOGICAL).
Who is sponsoring clinical trial NCT05689164?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.